Mielóma multiplex: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 3
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• TIGIT 0
• AMPK 0
• B7-H3 0
• NRAS 1
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

23+ intézményből 23, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R01

  Modulation of Bone Formation and Fracture Repair During Cancer Development

  Washington University· Saint Louis, Egyesült Államok· 577 398 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R50

  Curing Through Cooperation: Aligning Cooperative Groups to Investigate Novel Therapeutic Approaches to Cure Plasma Cell Dyscrasias

  Utah State Higher Education System--University of Utah· Salt Lake City, Egyesült Államok· 173 767 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R44

  Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma

  Cellsbin, Inc.· Branford, Egyesült Államok· 1 045 925 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · U01

  Comparative Modeling of Multiple Myeloma Prevention, Early Detection and Treatment Interventions

  Washington University· Saint Louis, Egyesült Államok· 848 978 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Overcoming CAR T cell resistance by tumor-restricted IL-12 driven anti-tumor immunity

  University of California Los Angeles· Los Angeles, Egyesült Államok· 477 666 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Svédország· EU contribution 2 000 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Németország· EU contribution 1 466 571 EUR· until 2031. okt.

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spanyolország· EU contribution 9 998 178 EUR· until 2031. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Németország· EU contribution 9 999 253 EUR· until 2028. máj.· 8 countries

10 of 334 running projects, newest first. Listed amounts together: 252,9 M USD + 35,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  NCT06953960· AbbVie· Forrás

• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  2025-525105-20-00· AbbVie Deutschland GmbH & Co. KG· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Distinct 5' and 3' coverage biases shape transcriptome interpretation in Nanopore direct RNA versus PCR-cDNA sequencing.

  BMC Genomics, 2026. júl.

• The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis.

  Br J Haematol, 2026. júl.

• Single-cell RNA sequencing analysis revealed a potential association between ELK3 expression and the progression of multiple myeloma.

  Front Immunol, 2026. ápr.

• De Novo Detection of Clonal Structure and Evolution in Single-Cell and Spatial Transcriptomes.

  Int J Mol Sci, 2025. nov.

• Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: insights from single-cell RNA sequencing in multiple myeloma.

  Immunopharmacol Immunotoxicol, 2025. nov.

• Unravelling cell heterogeneity and gene regulation mechanisms in multiple myeloma through single-cell RNA-seq.

  Methods, 2025. nov.

• Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.

  Leukemia, 2019. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.